Blanks Robert
Known title: See RemarksCIK: 0001815433
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 4,941 | $24K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,969 | $29K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 38,000 | $226K | 6/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,855 | $38K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Gift | 1,000 | $0 | 3/15/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,017 | $44K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 112,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,835 | $12K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,846 | $10K | 8/21/2023 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 33,333 | $114K | 6/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 33,333 | $121K | 6/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,835 | $10K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,394 | $10K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 26 | $50 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,405 | $3K | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 33 | $64 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 100,000 | $150K | 10/5/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 21,842 | $23K | 8/26/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 17 | $17 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,441 | $1K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,188 | $3K | 7/26/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 71,795 | $47K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,517 | $964 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,489 | $1000 | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,752 | $1K | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 40,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 643 | $638 | 11/22/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 250,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.